EN
Can DCTH's Liver Cancer Franchise Sustain Its Own Valuation Now?
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Delcath typically reports earnings before the market opens, meaning Day 0 reflects the first full trading session where investors react to results, and Day +1 captures follow-through.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-06 | +$2.84 (+22.49%) | $1.62 (12.83%) | -$0.36 (-2.33%) | $1.41 (9.11%) |
| 2026-05-07 | -$0.02 (-0.18%) | $1.45 (12.88%) | +$0.24 (+2.14%) | $0.46 (4.14%) |
| 2026-02-26 | -$1.21 (-11.85%) | $0.94 (9.19%) | -$0.10 (-1.11%) | $0.62 (6.93%) |
| 2025-11-04 | -$0.44 (-4.62%) | $0.96 (10.08%) | -$0.40 (-4.41%) | $0.60 (6.61%) |
| 2025-08-06 | +$0.12 (+1.14%) | $2.84 (27.04%) | -$0.45 (-4.23%) | $1.13 (10.62%) |
| 2025-05-08 | +$2.75 (+23.64%) | $1.65 (14.19%) | +$0.48 (+3.38%) | $1.61 (11.22%) |
| 2025-03-06 | -$0.21 (-1.56%) | $1.95 (14.52%) | -$0.22 (-1.66%) | $0.89 (6.77%) |
| 2024-11-08 | +$0.12 (+1.10%) | $2.02 (18.46%) | -$1.10 (-9.95%) | $1.48 (13.35%) |
| Avg Abs Move | 8.32% | 14.90% | 3.65% | 8.59% |
Delcath shares have historically been highly volatile around earnings, with an average absolute Day 0 move of 8.32% and an average Day +1 move of 3.65%. The most dramatic reaction came in August 2026, when the stock surged 22.49% on Day 0 following the Q2 beat, though it gave back 2.33% the next session. In May 2025, shares jumped 23.64% on Day 0, followed by a 3.38% gain on Day +1. Conversely, the February 2026 report triggered an -11.85% Day 0 decline.
The Day 0 range averages 14.90%, indicating substantial intraday volatility regardless of direction. Investors should expect significant price movement on November 9, with the magnitude likely determined by whether the company meets or beats the $-0.10 EPS estimate and provides constructive commentary on Q4 guidance, patient starts, and trial enrollment.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 14) |
| Expected Move | $1.87 (12.52%) |
| Expected Range | $13.07 to $16.81 |
| Implied Volatility | 122.03% |
The options market is pricing a 12.52% expected move through the November 20 expiration, slightly below the stock's historical average Day 0 move of 14.90% but well above the average Day +1 move of 8.59%. This suggests options traders are anticipating meaningful volatility but are pricing in a somewhat more muted reaction than the stock's recent history—particularly compared to the 22.49% Day 0 surge in August 2026. Given the elevated uncertainty around profitability and guidance, actual post-earnings movement could exceed the options-implied range if results or commentary significantly surprise in either direction.
Part 3: What Analysts Are Saying
Delcath Systems holds a Strong Buy consensus among analysts, with 5 Strong Buy ratings, 0 Moderate Buy ratings, 1 Hold rating, and no sell ratings. The average recommendation score of 4.67 reflects overwhelmingly bullish sentiment. The mean price target of $25.00 implies 67% upside from the current price of $14.93, with a high target of $32.00 and a low of $21.00.
Analyst sentiment has remained unchanged over the past month, with the same 5 Strong Buy and 1 Hold rating mix. The consistency reflects confidence in the long-term opportunity despite near-term profitability pressures. The $25 average target suggests analysts see the current valuation as attractive relative to the company's commercial trajectory and pipeline potential, though the wide range ($21-$32) indicates differing views on execution risk and the timeline to sustained profitability.
Part 4: Technical Picture
The Barchart Technical Opinion currently rates DCTH as a 40% Buy, up from 24% Buy a week ago but unchanged from 40% Buy a month ago. The recent improvement suggests short-term momentum has strengthened heading into earnings.
Timeframe Analysis:
- Short-term (Hold): Neutral signal indicates near-term momentum is mixed, with the stock consolidating ahead of the earnings release
- Medium-term (50% Buy): Moderate buy signal suggests the intermediate-term trend is cautiously positive as the stock holds above key moving averages
- Long-term (100% Buy): Strong buy signal reflects solid longer-term uptrend, with the stock up significantly over the past year
Trend Characteristics: The signal strength is rated as Average with direction Weakening, suggesting the technical setup is moderately supportive but losing some momentum as earnings approach.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $14.59 | 50-Day MA | $15.45 |
| 10-Day MA | $14.57 | 100-Day MA | $14.68 |
| 20-Day MA | $14.67 | 200-Day MA | $12.45 |
DCTH is trading at $14.93, positioned above its 5-day ($14.59), 10-day ($14.57), 20-day ($14.67), 100-day ($14.68), and 200-day ($12.45) moving averages, but below the 50-day ($15.45). The stock's position above the 200-day MA confirms the longer-term uptrend remains intact, while the dip below the 50-day suggests some recent consolidation. The 200-day MA at $12.45 represents a key support level, while the 50-day at $15.45 is immediate resistance. Overall, the technical setup is cautiously supportive heading into earnings, with the stock holding above most key averages but showing signs of near-term consolidation. A strong earnings beat could propel shares back above the 50-day MA, while a miss or weak guidance could test support at the 100-day or 20-day levels.